A Phase 3 study funded by Pfizer Inc. (NYSE:PFE) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential shift in how seasonal influenza is prevented.
Researchers reported that the experimental quadrivalent modRNA vaccine delivered higher efficacy against circulating flu strains, though it also produced more short-term reactions following vaccination.
